DR2 DataRelease

SDY40: Delineate innate immune responses in populations at risk (the elderly and the immunosuppressed) that are different from the general population
Status: New
Description: We will recruit adult (21-49 years of age), elderly (>50 years), ages as outlined in the RFA, or non-elderly but immunosuppressed (defined as taking at least 10 mg of prednisone daily for at least one month) participants from the Greater New Haven area and rheumatology clinics in the Yale-New Haven Healthcare System. Individuals of either gender and all ethnic groups will be eligible to participate.

We will stimulate monocytes and DCs in vitro with ligands of TLRs 1-9 and quantify the efficiency of stimulation by assessment of production of cytokines and inflammatory mediators. TLRs 10 and 11 will not be addressed at this time as ligands are not known. Lineage specific pro-inflammatory cytokines from PBMCs by FACs. We will quantify intracellular levels of TNFα and IL-6 by FACS from PBMCs in suspension on the day of isolation of the cells. This is essential to control for differences in cell composition in PBMCs isolated from different individuals, given the broad range of hematopoietic cells synthesizing TNFα and IL-6.

By using multi-color staining of PBMCs with lineage-specific fluorescent antibodies, we will identify lineages positive for intracellular cytokine production at the single cell level, and track potential age-associated changes in cell lineages. Our experimental approach will be to obtain monocytes/macrophages cells from young adult and elderly subjects, define their Mif genotype, and analyze their baseline and stimulus-induced production of MIF.

Patient samples for genotyping will be obtained from the pellet of the Ficoll-hypaque isolation of PBMCs and extracted DNA will be analyzed for Mif genotype by established, robotic methodology that requires <1 μg of DNA. Purified monocytes/macrophage will be studied for their baseline and stimulation-induced responses following protocols in place in our laboratory.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Innate Immune Responsiveness in the Elderly and the Immunosuppressed
DOI: 10.21430/M3EMF3OMS4
Subjects: 903
Study PI, contact:
NameOrganizationSite
Erol Fikrig Yale School of Medicine Yale University - School of Medicine
Publications:
Age-associated defect in human TLR-1/2 function.. J Immunol. Jan 2007. doi: - [Pubmed: 17202359]
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults.. J Infect Dis. Jun 2007. doi: b 2007 Apr 17. [Pubmed: 17471428]
Toll-like receptors in older adults.. J Am Geriatr Soc. Sep 2007. doi: - [Pubmed: 17767688]
Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion.. J Clin Invest. Oct 2007. doi: - [Pubmed: 17909632]
West Nile virus envelope protein inhibits dsRNA-induced innate immune responses.. J Immunol. Dec 2007. doi: - [Pubmed: 18056386]
Icam-1 participates in the entry of west nile virus into the central nervous system.. J Virol. Apr 2008. doi: 10.1128/JVI.02621-07. Epub 2008 Feb 6. [Pubmed: 18256150]
West nile virus attenuates activation of primary human macrophages.. Viral Immunol. Mar 2008. doi: 10.1089/vim.2007.0072. [Pubmed: 18355125]
Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly.. J Virol. Aug 2008. doi: 10.1128/JVI.00618-08. Epub 2008 May 28. [Pubmed: 18508883]
Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain.. J Virol. Sep 2008. doi: 10.1128/JVI.00314-08. Epub 2008 Jul 16. [Pubmed: 18632868]
RNA interference screen for human genes associated with West Nile virus infection.. Nature. Sep 2008. doi: 10.1038/nature07207. [Pubmed: 18690214]
Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing.. Immunity. Feb 2009. doi: 10.1016/j.immuni.2008.11.012. Epub 2009 Feb 5. [Pubmed: 19200759]
The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia.. FASEB J. Aug 2009. doi: 10.1096/fj.09-129445. Epub 2009 Apr 3. [Pubmed: 19346297]
Human innate immunosenescence: causes and consequences for immunity in old age.. Trends Immunol. Jul 2009. doi: 10.1016/j.it.2009.05.004. Epub 2009 Jun 21. [Pubmed: 19541535]
IL-10 signaling blockade controls murine West Nile virus infection.. PLoS Pathog. Oct 2009. doi: 10.1371/journal.ppat.1000610. Epub 2009 Oct 9. [Pubmed: 19816558]
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response.. J Immunol. Mar 2010. doi: 10.4049/jimmunol.0901022. Epub 2010 Jan 25. [Pubmed: 20100933]
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.. Lab Invest. Jun 2010. doi: 10.1038/labinvest.2010.73. Epub 2010 Apr 19. [Pubmed: 20404807]
Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults.. PLoS One. Jun 2010. doi: 10.1371/journal.pone.0011343. [Pubmed: 20596538]
Aging of the innate immune system.. Curr Opin Immunol. Aug 2010. doi: 10.1016/j.coi.2010.05.003. [Pubmed: 20667703]
Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I.. Nat Immunol. Oct 2010. doi: 10.1038/ni.1933. Epub 2010 Sep 5. [Pubmed: 20818395]
A paradoxical role for neutrophils in the pathogenesis of West Nile virus.. J Infect Dis. Dec 2010. doi: 10.1086/657416. Epub 2010 Nov 4. [Pubmed: 21050124]
Impaired interferon signaling in dendritic cells from older donors infected in vitro with West Nile virus.. J Infect Dis. May 2011. doi: 10.1093/infdis/jir048. Epub 2011 Mar 11. [Pubmed: 21398396]
Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly.. Aging Cell. Feb 2012. doi: 10.1111/j.1474-9726.2011.00759.x. Epub 2011 Nov 28. [Pubmed: 22023165]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 10087
Flow Cytometry 2626
PCR 1032
Q-PCR 808
Western Blot 336
Clinical Assessments:None
SDY41: Determine whether differences in TLR-responsiveness alter susceptibility to Biodefense priority pathogens using WN virus as a paradigm or responsiveness to vaccination using influenza as a model shared to Semi-Public Workspace (SPW) Project
Status: New
Description: The Study's goal is to quantify the innate immune response of macrophages from the three populations identified in the study titled 'Delineate innate immune responses in populations at risk (the elderly and the immunosuppressed) that are different from the general population', to agents of Biodefense, using West Nile virus infection and influenza vaccination as models.

In addition, by recruiting patients who have had West Nile virus infection or received influenza vaccine, we will assess the efficiency of immune responses to these potential agents of bioterrorism.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Innate Immune Responsiveness in the Elderly and the Immunosuppressed
DOI: 10.21430/M3KDRIKJOB
Subjects: 903
Study PI, contact:
NameOrganizationSite
Erol Fikrig Yale School of Medicine Yale University - School of Medicine
Publications:
Age-associated defect in human TLR-1/2 function.. J Immunol. Jan 2007. doi: - [Pubmed: 17202359]
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults.. J Infect Dis. Jun 2007. doi: b 2007 Apr 17. [Pubmed: 17471428]
Toll-like receptors in older adults.. J Am Geriatr Soc. Sep 2007. doi: - [Pubmed: 17767688]
Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion.. J Clin Invest. Oct 2007. doi: - [Pubmed: 17909632]
West Nile virus envelope protein inhibits dsRNA-induced innate immune responses.. J Immunol. Dec 2007. doi: - [Pubmed: 18056386]
Icam-1 participates in the entry of west nile virus into the central nervous system.. J Virol. Apr 2008. doi: 10.1128/JVI.02621-07. Epub 2008 Feb 6. [Pubmed: 18256150]
West nile virus attenuates activation of primary human macrophages.. Viral Immunol. Mar 2008. doi: 10.1089/vim.2007.0072. [Pubmed: 18355125]
Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly.. J Virol. Aug 2008. doi: 10.1128/JVI.00618-08. Epub 2008 May 28. [Pubmed: 18508883]
Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain.. J Virol. Sep 2008. doi: 10.1128/JVI.00314-08. Epub 2008 Jul 16. [Pubmed: 18632868]
RNA interference screen for human genes associated with West Nile virus infection.. Nature. Sep 2008. doi: 10.1038/nature07207. [Pubmed: 18690214]
Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing.. Immunity. Feb 2009. doi: 10.1016/j.immuni.2008.11.012. Epub 2009 Feb 5. [Pubmed: 19200759]
The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia.. FASEB J. Aug 2009. doi: 10.1096/fj.09-129445. Epub 2009 Apr 3. [Pubmed: 19346297]
Human innate immunosenescence: causes and consequences for immunity in old age.. Trends Immunol. Jul 2009. doi: 10.1016/j.it.2009.05.004. Epub 2009 Jun 21. [Pubmed: 19541535]
IL-10 signaling blockade controls murine West Nile virus infection.. PLoS Pathog. Oct 2009. doi: 10.1371/journal.ppat.1000610. Epub 2009 Oct 9. [Pubmed: 19816558]
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response.. J Immunol. Mar 2010. doi: 10.4049/jimmunol.0901022. Epub 2010 Jan 25. [Pubmed: 20100933]
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.. Lab Invest. Jun 2010. doi: 10.1038/labinvest.2010.73. Epub 2010 Apr 19. [Pubmed: 20404807]
Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults.. PLoS One. Jun 2010. doi: 10.1371/journal.pone.0011343. [Pubmed: 20596538]
Aging of the innate immune system.. Curr Opin Immunol. Aug 2010. doi: 10.1016/j.coi.2010.05.003. [Pubmed: 20667703]
Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I.. Nat Immunol. Oct 2010. doi: 10.1038/ni.1933. Epub 2010 Sep 5. [Pubmed: 20818395]
A paradoxical role for neutrophils in the pathogenesis of West Nile virus.. J Infect Dis. Dec 2010. doi: 10.1086/657416. Epub 2010 Nov 4. [Pubmed: 21050124]
Impaired interferon signaling in dendritic cells from older donors infected in vitro with West Nile virus.. J Infect Dis. May 2011. doi: 10.1093/infdis/jir048. Epub 2011 Mar 11. [Pubmed: 21398396]
Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly.. Aging Cell. Feb 2012. doi: 10.1111/j.1474-9726.2011.00759.x. Epub 2011 Nov 28. [Pubmed: 22023165]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 154
Q-PCR 1026
Clinical Assessments:None
SDY61: Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine)
Status: New
Description: Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Biological Analysis of Innate and Adaptive Responses to Vaccination
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3FH0SA2W0
Subjects: 12
Study PI, contact:
NameOrganizationSite
Bali Pulendran Emory Vaccine Center, Emory University Emory Vaccine Center
Publications:
Systems biology of vaccination for seasonal influenza in humans.. Nat Immunol. Jul 2011. doi: 10.1038/ni.2067. [Pubmed: 21743478]
Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.. Immunity. Dec 2015. doi: 10.1016/j.immuni.2015.11.012. [Pubmed: 26682988]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29614]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 4
Hemagglutination Inhibition 54
Q-PCR 27
Transcription profiling by array 27
Clinical Assessments:None
SDY62: Vaccination with drifted variants of H5 hemagglutinin protein elicits a broadened antibody response
Status: New
Description: Substantial H5 influenza HA directed immunity is elicited after vaccination of human subjects who had been previously immunized with a drifted H5 HA variant. We sought to investigate the characteristics of H5 HA specific immune responses in more depth by developing an animal model of H5 HA vaccination using drift variants of recombinant H5 HA proteins. HA proteins derived from influenzas A/Vietnam/1203/04 (Clade 1) and A/Indonesia/05/05 (Clade 2.1) were chosen. The sequence of vaccination consisted of two doses of homologous protein, followed by one additional dose of the homologous or heterologous, drifted HA protein. Each dose of HA was combined with CpG as an adjuvant and was injected subcutaneously. All the animals exhibited a serum IgG antibody response that cross-reacted with both HAs in an ELISA. However, those animals that received the drifted variant exhibited higher reactivity to the heterologous HA. Competitive ELISA of serum from drift-variant recipients showed evidence of antibody focusing towards the drifted HA, suggesting modification of the response towards improved cross-reactivity, though development of neutralizing antibodies was limited. Nevertheless, animals were protected against live-virus challenge, and passive transfer of serum was sufficient to confer protection to otherwise naive mice, indicating that both neutralizing and non-neutralizing antibodies offer some degree of protection. These findings suggest that pre-vaccination against H5 influenza has the potential to prime immunity against emerging drifted H5 strains, and could also lower the dose requirements of vaccination in the event of a pandemic.
Program/Contract:
ProgramContract
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) New York Influenza Center of Excellence
DOI: 10.21430/M3RH4FT7XC
Subjects: 86
Study PI, contact:
NameOrganizationSite
Felix Santiago University of Rochester ROC034
Publications:
Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.. Vaccine. Nov 2011. doi: 10.1016/j.vaccine.2011.09.069. Epub 2011 Sep 28. [Pubmed: 21963871]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 108
Virus Neutralization 66
Clinical Assessments:None
SDY64: Aerosol vaccination in mice
Status: New
Description: Evaluation of the parameters required for effective aerosol delivery of influenza virus in mice using controlled 20 and 30 m MMAD particle aerosols as proof of concept for LAIV aerosol delivery
Program/Contract:
ProgramContract
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3DU77M662
Subjects: 36
Study PI, contact:
NameOrganizationSite
Ralph Tripp College of Veterinary Medicine, University of Georgia
Publications:
Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice.. Vaccine. Mar 2011. doi: 10.1016/j.vaccine.2011.01.059. Epub 2011 Feb 5. [Pubmed: 21300100]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 168
Hemagglutination Inhibition 14
TCID50 62
Clinical Assessments:None
SDY146: Immune response evaluation in patients treated with TNF-alpha blockade (anti-TNF)
Status: New
Description: This project is to develop and apply the University of Rochester Program for Biodefense of Immunocompromised Populations (URPBIP) to the systematic study of human immune function with the goal of identifying defective mechanisms of immune response in patients treated with TNF-alpha blockade (anti-TNF). Studies are designed to detect changes that are likely to be induced by sustained TNF-alpha neutralization in the immune homeostasis and immune responsiveness of B-cells, T-cells and Dendritic cells. Although the study is not specifically designed to understand immune function in the elderly, the inclusion of a subset of patients and controls over and under 50 may result in the discovery of age-specific defects.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Function and Biodefense in patients with TNF-a Blockade
DOI: 10.21430/M3QXQFGTK5
Subjects: 225
Study PI, contact:
NameOrganizationSite
Ignacio Sanz University of Rochester Medical Center University of Rochester Medical Center
Publications:
Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.. Vaccine. Apr 2010. doi: 10.1016/j.vaccine.2010.02.088. Epub 2010 Mar 16. [Pubmed: 20298818]
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.. Arthritis Res Ther. - 2011. doi: 10.1186/ar3542. Epub 2011 Dec 16. [Pubmed: 22177419]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 2003
Clinical Assessments:None
SDY162: Immunologic and genomic signatures of response to Hepatitis C Virus infection.
Status: New
Description: Examine the immune response in primary immune cells from subjects who have spontaneously cleared HCV compared to HCV chronically infected subjects
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Defining signatures for immune responsiveness by functional systems immunology HIPC1
DOI: 10.21430/M3TI5NZ7VL
Subjects: 20
Study PI, contact:
NameOrganizationSite
David Hafler Yale Yale
Publications:
Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.. Clin Vaccine Immunol. Feb 2013. doi: 10.1128/CVI.00530-12. Epub 2012 Dec 5. [Pubmed: 23220997]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 80
Clinical Assessments:None
SDY165: Characterization of in vitro Stimulated B Cells from Human Subjects
Status: New
Description: During the human B cell (Bc) recall response, rapid cell division results in multiple Bc subpopulations. RNA microarray and functional analyses showed that proliferating CD27lo cells are a transient pre-plasmablast population, expressing genes associated with Bc receptor editing. Undivided cells had an active transcriptional program of non-ASC B cell functions, including cytokine secretion and costimulation, suggesting a link between innate and adaptive Bc responses. Transcriptome analysis suggested a gene regulatory network for CD27lo and CD27hi Bc differentiation.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M3GTK55VEV
Subjects: 15
Study PI, contact:
NameOrganizationSite
Martin Zand University of Rochester Medical Center University of Rochester Medical Center
Publications:
Functionally Distinct Subpopulations of CpG-Activated Memory B Cells.. Sci Rep. - 2012. doi: 10.1038/srep00345. Epub 2012 Mar 30. [Pubmed: 22468229]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 18
ELISPOT 21
Flow Cytometry 58
Q-PCR 2954
Clinical Assessments:None
SDY167: VRC304 - A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP) Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults
Status: New
Description: The primary objective was to evaluate the safety and tolerability of an investigational vaccine VRC-AVIDNA036-00-VP in humans at doses 1 mg and 4 mg administered intramuscularly using a needle-free injection system. The secondary objectives included evaluation of whether VRC-AVIDNA036-00-VP (at doses 1 mg and 4 mg) induced antibodies as assessed by an HAI assay at Day 0 and Week 12. Exploratory analyses included evaluation of the immunogenicity of VRC-AVIDNA036-00-VP at doses 1 mg and 4 mg using intracellular cytokine staining, ELISpot, neutralizing antibody assay, HAI assay to H1 or H3HA or other immunological assays at time intervals between Day 0 and Week 42.
Program/Contract:
ProgramContract
NIAID Vaccine Research Center (VRC) NIAID Vaccine Research Center (VRC)
DOI: 10.21430/M3SGHW16WZ
Subjects: 45
Study PI, contact:
NameOrganizationSite
Julie Ledgerwood Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID)
Publications:
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.. Clin Vaccine Immunol. Nov 2012. doi: 10.1128/CVI.05663-11. Epub 2012 Sep 5. [Pubmed: 22956656]
Resources:
ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00408109]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 430
ELISPOT 300
Flow Cytometry 874
Hemagglutination Inhibition 44
Virus Neutralization 88
Clinical Assessments:None
SDY196: Responses to Influenza Vaccination in Systemic Lupus Year 1 2005-2006
Status: New
Description: Influenza is an important pathogen in the United States, with approximately 20,000 deaths per year, mainly among elderly people or those with underlying medical conditions that increase susceptibility to complications from the disease. In addition, considerable morbidity is associated with influenza with a significant impact in productivity in the workplace and home. Influenza has the potential for much more serious consequences as demonstrated by the appearance of four world-wide pandemics in the last century. In principle, serious influenza outbreaks can be prevented by vaccination. However, vaccination is complicated by two features: First, the influenza virus undergoes frequent mutations in the genes encoding the surface proteins hemagglutinin (HA) and neuraminidase (NA), leading to the need to reformulate the vaccine every year. Second, the appearance of the rapidity with which influenza infections can spread. Thus, influenza holds significant potential as a bioterrorism agent. Lupus patients have an increased risk of infection and mount lower responses to vaccinations. The objectives of this study will use genetic, cellular and humoral techniques to identify and explain abnormalities in the immune response to influenza vaccination in lupus patients. The results will clarify vaccine effectiveness among affected patients, increase the understanding of immune dysregulation in lupus, and aid in establishing guidelines for the effective vaccination of lupus patients. The benefits to the subjects are not direct; however, information gained may improve responses of reducing or preventing influenza among the affected population. Additionally, with an increased understanding of the processes of lupus, targets for disease intervention or strategies for treatment may appear.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Responses to Influenza Vaccination in Systemic Lupus
DOI: 10.21430/M3ABJS44K6
Subjects: 62
Study PI, contact:
NameOrganizationSite
Linda Thompson Oklahoma Medical Research Foundation (OMRF) Oklahoma Medical Research Foundation
Publications:
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.. Arthritis Rheum. Aug 2011. doi: 10.1002/art.30388. [Pubmed: 21598235]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 118
ELISPOT 248
Flow Cytometry 1868
Hemagglutination Inhibition 124
Western Blot 46
Clinical Assessments:
Medical History
SLE Panel
SDY197: Responses to Influenza Vaccination in Systemic Lupus Year 2 2006-2007
Status: New
Description: Influenza is an important pathogen in the United States, with approximately 20,000 deaths per year, mainly among elderly people or those with underlying medical conditions that increase susceptibility to complications from the disease. In addition, considerable morbidity is associated with influenza with a significant impact in productivity in the workplace and home. Influenza has the potential for much more serious consequences as demonstrated by the appearance of four world-wide pandemics in the last century. In principle, serious influenza outbreaks can be prevented by vaccination. However, vaccination is complicated by two features: First, the influenza virus undergoes frequent mutations in the genes encoding the surface proteins hemagglutinin (HA) and neuraminidase (NA), leading to the need to reformulate the vaccine every year. Second, the appearance of the rapidity with which influenza infections can spread. Thus, influenza holds significant potential as a bioterrorism agent. Lupus patients have an increased risk of infection and mount lower responses to vaccinations. The objectives of this study will use genetic, cellular and humoral techniques to identify and explain abnormalities in the immune response to influenza vaccination in lupus patients. The results will clarify vaccine effectiveness among affected patients, increase the understanding of immune dysregulation in lupus, and aid in establishing guidelines for the effective vaccination of lupus patients. The benefits to the subjects are not direct; however, information gained may improve responses of reducing or preventing influenza among the affected population. Additionally, with an increased understanding of the processes of lupus, targets for disease intervention or strategies for treatment may appear.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Responses to Influenza Vaccination in Systemic Lupus
DOI: 10.21430/M3FD1QTLQQ
Subjects: 63
Study PI, contact:
NameOrganizationSite
Linda Thompson Oklahoma Medical Research Foundation (OMRF) Oklahoma Medical Research Foundation
Publications:
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.. Arthritis Rheum. Aug 2011. doi: 10.1002/art.30388. [Pubmed: 21598235]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 126
ELISPOT 252
Flow Cytometry 2331
Hemagglutination Inhibition 188
Western Blot 47
Clinical Assessments:
Medical History
SLE Panel
SDY198: Responses to Influenza Vaccination in Systemic Lupus Year 3 2007-2008
Status: New
Description: Influenza is an important pathogen in the United States, with approximately 20,000 deaths per year, mainly among elderly people or those with underlying medical conditions that increase susceptibility to complications from the disease. In addition, considerable morbidity is associated with influenza with a significant impact in productivity in the workplace and home. Influenza has the potential for much more serious consequences as demonstrated by the appearance of four world-wide pandemics in the last century. In principle, serious influenza outbreaks can be prevented by vaccination. However, vaccination is complicated by two features: First, the influenza virus undergoes frequent mutations in the genes encoding the surface proteins hemagglutinin (HA) and neuraminidase (NA), leading to the need to reformulate the vaccine every year. Second, the appearance of the rapidity with which influenza infections can spread. Thus, influenza holds significant potential as a bioterrorism agent. Lupus patients have an increased risk of infection and mount lower responses to vaccinations. The objectives of this study will use genetic, cellular and humoral techniques to identify and explain abnormalities in the immune response to influenza vaccination in lupus patients. The results will clarify vaccine effectiveness among affected patients, increase the understanding of immune dysregulation in lupus, and aid in establishing guidelines for the effective vaccination of lupus patients. The benefits to the subjects are not direct; however, information gained may improve responses of reducing or preventing influenza among the affected population. Additionally, with an increased understanding of the processes of lupus, targets for disease intervention or strategies for treatment may appear.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Responses to Influenza Vaccination in Systemic Lupus
DOI: 10.21430/M3D393V41D
Subjects: 74
Study PI, contact:
NameOrganizationSite
Linda Thompson Oklahoma Medical Research Foundation (OMRF) Oklahoma Medical Research Foundation
Publications:
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.. Arthritis Rheum. Aug 2011. doi: 10.1002/art.30388. [Pubmed: 21598235]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 148
ELISPOT 296
Flow Cytometry 2733
Hemagglutination Inhibition 223
Western Blot 52
Clinical Assessments:
Medical History
SLE Panel
SDY199: Responses to Influenza Vaccination in Systemic Lupus Year 4 2008-2009
Status: New
Description: Influenza is an important pathogen in the United States, with approximately 20,000 deaths per year, mainly among elderly people or those with underlying medical conditions that increase susceptibility to complications from the disease. In addition, considerable morbidity is associated with influenza with a significant impact in productivity in the workplace and home. Influenza has the potential for much more serious consequences as demonstrated by the appearance of four world-wide pandemics in the last century. In principle, serious influenza outbreaks can be prevented by vaccination. However, vaccination is complicated by two features: First, the influenza virus undergoes frequent mutations in the genes encoding the surface proteins hemagglutinin (HA) and neuraminidase (NA), leading to the need to reformulate the vaccine every year. Second, the appearance of the rapidity with which influenza infections can spread. Thus, influenza holds significant potential as a bioterrorism agent. Lupus patients have an increased risk of infection and mount lower responses to vaccinations. The objectives of this study will use genetic, cellular and humoral techniques to identify and explain abnormalities in the immune response to influenza vaccination in lupus patients. The results will clarify vaccine effectiveness among affected patients, increase the understanding of immune dysregulation in lupus, and aid in establishing guidelines for the effective vaccination of lupus patients. The benefits to the subjects are not direct; however, information gained may improve responses of reducing or preventing influenza among the affected population. Additionally, with an increased understanding of the processes of lupus, targets for disease intervention or strategies for treatment may appear.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Responses to Influenza Vaccination in Systemic Lupus
DOI: 10.21430/M39YLN3479
Subjects: 69
Study PI, contact:
NameOrganizationSite
Linda Thompson Oklahoma Medical Research Foundation (OMRF) Oklahoma Medical Research Foundation
Publications:
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.. Arthritis Rheum. Aug 2011. doi: 10.1002/art.30388. [Pubmed: 21598235]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 138
ELISPOT 276
Flow Cytometry 2440
Hemagglutination Inhibition 207
Western Blot 43
Clinical Assessments:
Medical History
SLE Panel
SDY200: Responses to Influenza Vaccination in Systemic Lupus Year 5 2009-2010
Status: New
Description: Influenza is an important pathogen in the United States, with approximately 20,000 deaths per year, mainly among elderly people or those with underlying medical conditions that increase susceptibility to complications from the disease. In addition, considerable morbidity is associated with influenza with a significant impact in productivity in the workplace and home. Influenza has the potential for much more serious consequences as demonstrated by the appearance of four world-wide pandemics in the last century. In principle, serious influenza outbreaks can be prevented by vaccination. However, vaccination is complicated by two features: First, the influenza virus undergoes frequent mutations in the genes encoding the surface proteins hemagglutinin (HA) and neuraminidase (NA), leading to the need to reformulate the vaccine every year. Second, the appearance of the rapidity with which influenza infections can spread. Thus, influenza holds significant potential as a bioterrorism agent. Lupus patients have an increased risk of infection and mount lower responses to vaccinations. The objectives of this study will use genetic, cellular and humoral techniques to identify and explain abnormalities in the immune response to influenza vaccination in lupus patients. The results will clarify vaccine effectiveness among affected patients, increase the understanding of immune dysregulation in lupus, and aid in establishing guidelines for the effective vaccination of lupus patients. The benefits to the subjects are not direct; however, information gained may improve responses of reducing or preventing influenza among the affected population. Additionally, with an increased understanding of the processes of lupus, targets for disease intervention or strategies for treatment may appear.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Responses to Influenza Vaccination in Systemic Lupus
DOI: 10.21430/M3ZR6IH181
Subjects: 73
Study PI, contact:
NameOrganizationSite
Linda Thompson Oklahoma Medical Research Foundation (OMRF) Oklahoma Medical Research Foundation
Publications:
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.. Arthritis Rheum. Aug 2011. doi: 10.1002/art.30388. [Pubmed: 21598235]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 134
ELISPOT 280
Flow Cytometry 635
Hemagglutination Inhibition 207
Clinical Assessments:
Medical History
SDY201: Responses to Influenza Vaccination in Systemic Lupus Year 6 2010-2011
Status: New
Description: Influenza is an important pathogen in the United States, with approximately 20,000 deaths per year, mainly among elderly people or those with underlying medical conditions that increase susceptibility to complications from the disease. In addition, considerable morbidity is associated with influenza with a significant impact in productivity in the workplace and home. Influenza has the potential for much more serious consequences as demonstrated by the appearance of four world-wide pandemics in the last century. In principle, serious influenza outbreaks can be prevented by vaccination. However, vaccination is complicated by two features: First, the influenza virus undergoes frequent mutations in the genes encoding the surface proteins hemagglutinin (HA) and neuraminidase (NA), leading to the need to reformulate the vaccine every year. Second, the appearance of the rapidity with which influenza infections can spread. Thus, influenza holds significant potential as a bioterrorism agent. Lupus patients have an increased risk of infection and mount lower responses to vaccinations. The objectives of this study will use genetic, cellular and humoral techniques to identify and explain abnormalities in the immune response to influenza vaccination in lupus patients. The results will clarify vaccine effectiveness among affected patients, increase the understanding of immune dysregulation in lupus, and aid in establishing guidelines for the effective vaccination of lupus patients. The benefits to the subjects are not direct; however, information gained may improve responses of reducing or preventing influenza among the affected population. Additionally, with an increased understanding of the processes of lupus, targets for disease intervention or strategies for treatment may appear.
Program/Contract:
ProgramContract
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations Responses to Influenza Vaccination in Systemic Lupus
DOI: 10.21430/M35J0WA7CR
Subjects: 34
Study PI, contact:
NameOrganizationSite
Linda Thompson Oklahoma Medical Research Foundation (OMRF) Oklahoma Medical Research Foundation
Publications:
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.. Arthritis Rheum. Aug 2011. doi: 10.1002/art.30388. [Pubmed: 21598235]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 68
ELISPOT 136
Flow Cytometry 860
Hemagglutination Inhibition 102
Clinical Assessments:
Medical History
SLE Panel
Back to top